The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world,
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …

Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

Background Ixazomib is an oral proteasome inhibitor that is currently being studied for the
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces
apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has …

Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells, so new
approaches to treatment are needed. T-cell therapies are a promising approach for treating …